CD22 and neoplasm: A similar set of studies on treatment with double the dose of 131I-cPAM4 with gemcitabine resulted in superior antitumor activity with tumor growth inhibition and 2-fold increased median survival time than treatment with 131I-hLL2 (a isotype-matched, humanized LL2 anti CD22 antibody) with gemcitabine.